Motivation
Conditions
Brief summary
Tetrahydrocannabivarin (THCV) is a rare cannabinoid and is a homologue of THC that differs only in the length of the alkyl side chain (3C vs 5C, respectively). Pre-clinical and clinical trials have shown that THCV has medical potential as a neuroprotectant, anti-inflammatory, anti-anxiety, and most notably as a therapeutic to improve glycemic control in type 2 diabetic patients. Several THCV products are available in states with recreational cannabis. Anecdotal reports from adult cannabis users indicate that THCV provides an energizing, focusing and euphoric high-while still creating a lucid, uplifting experience. Additionally, unlike THC-dominant products, THCV was not reported to increase appetite. Other anecdotal comments referring to increased ability to focus for long periods of time and being more active were common. Given anecdotal evidence, which shows that THCV is activating and improving focus, this provides rationale and justification to conduct a clinical research study to further test and understand whether THCV improves motivation, focus, level of energy, and does not stimulate appetite in healthy adults.
Detailed description
The rationale for this study is to determine the effect of a consumer-grade, state-legal formulation of cannabinoids including Tetrahydrocannabivarin (THCV) on motivation, energy level, focus, and appetite. A consumer-driven, decentralized observational clinical research study is therefore well suited to examine the effect of this formulation in healthy individuals. The investigators will examine the outcomes in a broad age-range of adults who have chosen to try these products. The study will incorporate participant reported outcomes and surveys collected after each product use session to engage the participant in their typical day-to-day activities. There is no physician-patient relationship as part of this research since the participant as a consumer is making the informed choice to take the products and take part in the observational process with self-reported measures. Findings from this study will contribute knowledge toward the design of future cannabis research studies and the improvement of the product formulation. A new study questionnaire was developed as no existing questionnaire would be able to capture all interest areas of this study in a holistic manner. Other questionnaires related to focus, attention, concentration, fatigue, work, and motivation were assessed and used to support the study questionnaire development.
Interventions
BEHAVIORALStudy Product, THC Product, Placebo
Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Sponsors
People Science, Inc.
Phylos Bioscience, Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adults age \> 21 years old 2. Work / study / play in an environment that requires focus 3. Able to read and understand English 4. Able to read, understand, and provide informed consent 5. Able to use a personal smartphone device and download Chloe by People Science 6. Able to complete study assessments over the course of up to 14 days 7. Familiar with the use of cannabis and its effects 8. Able to tolerate at least 5mg THC 9. Willingness to abstain from use of any THC containing products during study product use days 10. Willingness to abstain from use of alcohol during study product use days 11. Greater Los Angeles area residents only
Exclusion criteria
1. Participants who do not have a smartphone and/or internet access 2. Any known adverse effects from taking cannabis 3. Concomitant Therapies: Currently taking medication for ADHD or psychotropic medications 4. Other Illnesses or Conditions: Participants who have the following co-morbidities are excluded: 1. History or currently undergoing product use for substance abuse disorders 2. Currently pregnant, planning to become pregnant within the next month, or breastfeeding 3. Allergies to formulation ingredients 4. Current or prior psychotic disorder 5. Immunosuppressive product uses, including organ transplant participants, active immunotherapy for cancer product use 6. Any condition that is considered by investigator to be a contraindication to cannabis (e.g. specific drug-use interaction, unstable cardiac arrhythmia)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To observe the effect of various cannabinoid-containing products on motivation. | 3 weeks | Change in average motivation score by 1 point as measured by a 10-point visual analogue rating scale (VAS) collected between cannabinoid and placebo use sessions. The scale is between 1-10, where 1 denotes 'Strongly Disagree' and 10 denotes 'Strongly Agree.' |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To observe the effect of cannabinoid products on motivation, energy level, focus, and appetite (MEFA). | 3 weeks | Change in average score by 1 point as measured by a 10-point visual analogue rating scale (VAS) between the cannabinoid and placebo use sessions. The scale is between 1-10, where 1 denotes 'Strongly Disagree' and 10 denotes 'Strongly Agree.' |
Other
| Measure | Time frame | Description |
|---|---|---|
| To observe changes in overall symptoms and quality of life. | 3 weeks | Changes in overall symptoms and quality of life to be assessed based on a qualitative evaluation of study participant experiences. |
Countries
United States
Contacts
Primary ContactAmy Kazaryan, MPhil
Backup ContactCrisel Erfe, MD
Outcome results
None listed